NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B

NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B

Аnalogues of nucleos(t)ides (AN) such as lamivudine (LAM), telbivudine (TBV), adefovir (ADP), entecavir (ENT) are widely used for the treatment of chronic hepatitis B (CHB). However, the prolonged treatment using these drugs often leads to the development of drug resistance. The most common substitu...

Full description

Bibliographic Details
Main Authors:	E. A. Elpaeva, A. B. Komissarov, M. M. Pisareva, M. P. Grudinin, O. I. Kiselev
Format:	Article
Language:	Russian
Published:	Sankt-Peterburg : NIIÈM imeni Pastera 2015-12-01
Series:	Инфекция и иммунитет
Subjects:	hepatitis b virus real-time pcr mutations sequencing chronic hepatitis b аnalogues of nucleos(t)ides
Online Access:	https://www.iimmun.ru/iimm/article/view/331

Similar Items

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
by: Sang Kyung Jung, et al.
Published: (2015-03-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)

Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients
by: Jong Hwa Na, et al.
Published: (2021-06-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
by: Margarita Papatheodoridi, et al.
Published: (2020-02-01)

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice
by: Mingfan Geng, et al.
Published: (2017-09-01)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
by: Tao Li, et al.
Published: (2018-01-01)

Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B
by: E K Ibragimov, et al.
Published: (2019-02-01)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
by: Anna Maisa, et al.
Published: (2021-05-01)

The effect of nucleos(t)ide analogues on clinical outcomes of patients treated with transarterial chemoembolization and radiofrequency ablation for hepatitis B virus-related hepatocellular carcinoma
by: Jae Min Park, et al.
Published: (2021-09-01)

Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B
by: Fa-Da Wang, et al.
Published: (2022-06-01)

Early and late recurrence of surgically resected hepatitis B virus-related hepatocellular carcinoma on nucleos(t)ide analogues therapy
by: Chi-Jung Wu, et al.
Published: (2021-08-01)

Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study
by: Yi-Cheng Chen, et al.
Published: (2020-05-01)

Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
by: Ying-Nan Tsai, et al.
Published: (2024-01-01)

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy
by: Yachao Tao, et al.
Published: (2022-02-01)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
by: Zhang C, et al.
Published: (2016-03-01)

Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy
by: Er-Mei Li, et al.
Published: (2021-08-01)

Baseline Circulating miR-125b Levels Predict a High FIB-4 Index Score in Chronic Hepatitis B Patients after Nucleos(t)ide Analog Treatment
by: Jyun-Yi Wu, et al.
Published: (2022-11-01)

Treatment Adherence to Nucleos(t)ide Analogs in Chinese Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Single-Center Cross-Sectional Study
by: Li Y, et al.
Published: (2021-08-01)

Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B
by: Jie Peng, et al.
Published: (2015-01-01)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
by: Camila V Pereira, et al.
Published: (2016-04-01)

Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B
by: Linqing Xie, et al.
Published: (2019-07-01)

Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued
by: Liao G, et al.
Published: (2022-04-01)

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
by: Bei Jiang, et al.
Published: (2022-12-01)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
by: Yandi Xie, et al.
Published: (2023-06-01)

Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence
by: Akinobu Takaki, et al.
Published: (2015-07-01)

The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights
by: Fabrizio Fabrizi, et al.
Published: (2023-02-01)

Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy
by: Meng-Ju Lin, et al.
Published: (2023-07-01)

Editorial: Hepatitis B virus and host interactions in liver diseases
by: Yuen Gao, et al.
Published: (2023-05-01)

Hepatitis B viral factors and treatment responses in chronic hepatitis B
by: Chih-Lin Lin, et al.
Published: (2013-06-01)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
by: Li Liu
Published: (2020-02-01)

Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss
by: I-Chin Wu, et al.
Published: (2021-05-01)

Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance
by: Hung-Chih Yang, et al.
Published: (2014-01-01)

Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis
by: Yuhao Yao, et al.
Published: (2022-11-01)

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
by: Chih-Lin Lin, et al.
Published: (2020-10-01)

Hepatitis B virus associated cirrhosis: overview of prognostic and management
by: Marilena Stoian
Published: (2023-06-01)

Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir
by: Juhee Won, et al.
Published: (2022-07-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining
by: Xizhan Xu, et al.
Published: (2017-07-01)